NRAS and melanoma: In the large phase II trial, tunlametinib, in >80 patients with NRAS-mutant melanoma (NCT05217303) who had previously received immunotherapy, the confirmed ORR was 39.1% (95% CI, 27.1 to 52.1) with a median DOR of 6.1 months (95% CI, 4.2 to 8.9).